These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 6194983

  • 1. Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinine.
    Freise J, Magerstedt P, Schmid K.
    Enzyme; 1983; 30(3):209-12. PubMed ID: 6194983
    [Abstract] [Full Text] [Related]

  • 2. In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine.
    Freise J, Wittenberg H, Magerstedt P.
    Klin Wochenschr; 1989 Feb 01; 67(3):149-52. PubMed ID: 2467043
    [Abstract] [Full Text] [Related]

  • 3. Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.
    Freise J, Schmidt FW, Magerstedt P, Schmid K.
    Clin Biochem; 1985 Aug 01; 18(4):224-9. PubMed ID: 2412725
    [Abstract] [Full Text] [Related]

  • 4. Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.
    Hesse B, Lankisch PG, Kunze H.
    Pharmacol Res Commun; 1984 Jul 01; 16(7):637-45. PubMed ID: 6433363
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of porcine pancreas phospholipase A2 activation by gabexate mesilate.
    Schädlich HR, Büchler M, Beger HG.
    Klin Wochenschr; 1989 Feb 01; 67(3):160-2. PubMed ID: 2494376
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of gabexate mesilate on pancreatic phospholipase A2-mediated hydrolysis of ghost membranes.
    Nishijima J, Okamoto M, Nakaguchi K, Ogawa M, Yamano T, Mori T.
    Gen Pharmacol; 1985 Feb 01; 16(3):177-82. PubMed ID: 3926598
    [Abstract] [Full Text] [Related]

  • 7. Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes.
    Kunze H, Bohn E.
    Pharmacol Res Commun; 1983 May 01; 15(5):451-9. PubMed ID: 6412250
    [Abstract] [Full Text] [Related]

  • 8. Influence of aprotinin and gabexate mesilate on arachidonic acid release by the Ca-ionophore A 23187 in the lung.
    Seeger W, Wolf H, Graubert E, Moser U, Neuhof H, Roka L.
    Adv Exp Med Biol; 1983 May 01; 156():553-67. PubMed ID: 6190378
    [Abstract] [Full Text] [Related]

  • 9. Effects of the anti-inflammatory serine esterase inhibitor, FOY, on phospholipase A2 (EC 3.1.1.4) activity in rabbit polymorphonuclear leukocytes.
    Kunze H, Bohn E, Damerau B.
    Pharmacol Res Commun; 1983 Oct 01; 15(9):869-78. PubMed ID: 6417683
    [Abstract] [Full Text] [Related]

  • 10. [Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate].
    Freise J.
    Fortschr Med; 1983 Aug 25; 101(31-32):1432-6. PubMed ID: 6194089
    [Abstract] [Full Text] [Related]

  • 11. [Effect of FOY-305 on the activity and secretion of pancreatic enzymes in vitro].
    Stöckmann F, Göke B, Otto J, Lankisch PG, Creutzfeldt W.
    Z Gastroenterol; 1984 Jun 25; 22(6):311-7. PubMed ID: 6205521
    [Abstract] [Full Text] [Related]

  • 12. Cellular (thrombocytes, granulocytes) effects of proteinase inhibitors--gabexylate, gabexate mesilate (FOY) and aprotinin.
    Redl H, Schlag G, Paul E, Schiesser A.
    Resuscitation; 1986 Sep 25; 14(1-2):81-90. PubMed ID: 2431445
    [Abstract] [Full Text] [Related]

  • 13. [Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept].
    Kahle M, Klein U, König W, Martin U, Alles JU.
    Z Gastroenterol; 1985 Dec 25; 23(12):687-93. PubMed ID: 3937346
    [Abstract] [Full Text] [Related]

  • 14. FOY: [ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin.
    Ohno H, Kambayashi J, Chang SW, Kosaki G.
    Thromb Res; 1985 Dec 25; 24(5-6):445-52. PubMed ID: 6178174
    [No Abstract] [Full Text] [Related]

  • 15. Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein.
    Nakahara M.
    Arzneimittelforschung; 1983 Dec 25; 33(7):969-71. PubMed ID: 6194800
    [Abstract] [Full Text] [Related]

  • 16. [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
    Ino Y, Suzuki K, Sato T, Iwaki M.
    Nihon Yakurigaku Zasshi; 1986 Dec 25; 88(6):449-55. PubMed ID: 2435641
    [Abstract] [Full Text] [Related]

  • 17. Lysolecithin concentration in pancreatic tissue during therapy with phospholipase A2-inhibitors in acute necrotizing pancreatitis.
    Kahle M, König H, Filler RD.
    Klin Wochenschr; 1989 Feb 01; 67(3):177-9. PubMed ID: 2494378
    [Abstract] [Full Text] [Related]

  • 18. Effects of antiproteases (aprotinin and gabexate-mesilate) on the postischemic vascular response of the kidney.
    Pflüger H, Maier M, Binder BR.
    Urol Int; 1983 Feb 01; 38(3):150-7. PubMed ID: 6191420
    [Abstract] [Full Text] [Related]

  • 19. Gabexate mesilate (FOY) and aprotinin. A comparative study of the effects on trypsin-induced activation of the kinin and complement systems in vivo and in vitro.
    Lasson A, Balldin G, Ohlsson K.
    Hoppe Seylers Z Physiol Chem; 1984 Dec 01; 365(12):1409-15. PubMed ID: 6084637
    [Abstract] [Full Text] [Related]

  • 20. Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion.
    Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W.
    Digestion; 1984 Dec 01; 30(3):171-8. PubMed ID: 6209186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.